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ABSTRACT
PURPOSE: To compare the frequency of conjunctival HLA-DR expression (a surrogate marker for inflammation) in eyes treated with 
topical prostaglandin analogues versus eyes treated with other topical antiglaucomatous drugs.
METHODS: Patients diagnosed with primary open-angle glaucoma presenting indication for trabeculectomy were divided in groups 
according to the use or not of prostaglandin analogues. All subjects were treated with the maximum  tolerated dose of antiglaucomatous 
drugs until the date of the surgery. At the beginning of the surgical procedure, a 5 x 5 mm biopsy of the bulbar conjunctiva was collected, 
incubated with monoclonal anti-HLA-DR antibody and processed for histological analysis. 
RESULTS: Of the 31 eyes included (31 patients), 25 were under topical prostaglandin analogues (Group 1) and six under other topical 
pharmacological agents (Group 2).  Fourteen eyes of Group 1 (56%) and three of Group 2 (50 %) were positive for the inflammatory 
marker HLA-DR (P=1.0). The percentage of stained cells ranged from 15.49 to 48.09% (median: 27.61) in Group 1, and from 18.35 to 
28 (median: 20.71) in Group 2, with no differences statistically significant (p=0.33).  
CONCLUSION: The use of prostaglandin analogues did not increase conjunctival expression of HLA-DR compared to other topical 
antiglaucomatous agents. 
Key words: Leukocyte Antigens.  Glaucoma, Open-Angle. Immunology. Ophthalmic Solutions. Prostaglandin analogs.
RESUMO 
OBJETIVO: Comparar a frequência da expressão conjuntival de HLA-DR (marcador inflamatório) em olhos tratados com análogos de 
prostaglandinas de uso tópico com a frequência em olhos tratados com outros medicamentos. 
MÉTODOS: Pacientes com glaucoma primário de ângulo aberto apresentando indicação de trabeculectomia foram agrupados segundo 
o uso ou não de análogos de prostaglandinas. Todos os participantes foram tratados com medicação máxima tolerada até o momento 
da cirurgia. Ao início do procedimento cirúrgico, uma biópsia de 5 x 5 mm da conjuntiva bulbar foi coletada, incubada com anticorpo 
monoclonal anti-HLA-DR e processada para análise histológica
RESULTADOS: Dentre os 31 olhos incluídos (31 pacientes), 25 estavam em uso de análogos de prostaglandinas (Grupo 1) e seis 
em uso de outros agentes antiglaucomatosos (Grupo 2). Quatorze olhos do Grupo 1 (56%) e três do Grupo 2 (50%) apresentaram 
positividade para o marcador HLA-DR (p=1,0). A porcentagem de células coradas variou de 15,49 a 48,09% (mediana: 27,61%) no 
Grupo 1 e de 18,35 a 28% (mediana: 20,71%) no Grupo 2, com diferenças não estatisticamente significativas (p=0,33).  
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CONCLUSÃO: O uso de análogos de prostaglandinas não aumenta a expressão conjuntival de HLA-DR comparado com outros 
medicamentos tópicos para o tratamento de glaucoma. 
Descritores: Antigenos Leucocitários.  Glaucoma de Ângulo Aberto. Imunologia. Soluções Oftálmicas. Prostaglandinas Sintéticas.
Introduction
Glaucoma affects up to 60.5 million people worldwide, 
and more than 8 million of them are blind1. Medical therapy is 
the first choice therapy to reduce intraocular pressure and reduce 
the risk of visual field loss2. Among topical agents, prostaglandin 
analogues are currently the first-line therapy for glaucoma3, and 
some of the side-effects related to their use are iris pigmentation, 
transient conjunctival hyperemia4, corneal punctate staining5, 
squamous metaplasia6 and subclinical conjunctival inflammatory 
reaction that, although subclinical, may be detected by 
inflammatory markers, such as HLA-DR, expressed on epithelial 
cells7-10. 
There are studies in the literature describing that chronic 
topical therapy for glaucoma increases the risk of trabeculectomy 
failure, and that the preoperative conjunctival inflammation 
caused by the chronic antiglaucomatous medication would be 
involved in this process11. But although most of the studies report 
conjunctival inflammation in prostaglandin analogues users7,8,10,12, 
this feature may also be present in patients under the use of other 
antiglaucomatous drugs9,10,13-15.
Guenoun et al.16 studied, in vitro, conjunctiva-derived 
cells under the action of prostaglandin analogues in commercial 
solutions, prostaglandin F2 alpha, TNF-alpha, and of benzalkonium 
chloride (BAK). The results suggested that toxicity is induced by 
the preservative rather than the medication itself.  Uusitalo et al.17 
reported that even patients using preservative-free prostaglandin 
analog may present conjunctival expression of HLA-DR17. 
As the success of glaucoma surgical treatment depends on 
the status of the conjunctival and subconjunctival tissue that will be 
part of the surgical bleb11, it is important to analyze if prostaglandin 
analogues are able to induce subclinical inflammation, also if this 
inflammation is higher than the one caused by other topic agents. 
In this study, we selected patients with primary open-
angle glaucoma with indication to trabeculectomy surgery, divided 
them in groups according to the use or not of topical prostaglandin 
analogues, and compared the conjunctival expression of HLA-DR. 
Methods
The investigation was carried out according to Helsinki 
Declaration (Medical School of Ribeirao Preto University Hospital 
Ethics Committee protocol number 15582/2005).  The expression 
of the inflammatory marker HLA-DR was analyzed in biopsies 
of the bulbar conjunctiva from patients diagnosed with primary 
open-angle glaucoma presenting indication for trabeculectomy, 
followed at the Glaucoma Outpatient Clinic of the University 
Hospital, Faculty of Medicine of Ribeirao Preto-University of Sao 
Paulo. 
Subjects were divided in two groups according to the use 
or not of topic prostaglandin, and exclusion criteria were: presence 
of pterygium18, signs of clinical inflammation, and any type of 
previous surgery in the studied eye. All patients were treated with 
the maximum  tolerated dose of antiglaucomatous drugs until the 
date of the surgery.  
At the beginning of the surgical procedure, a 5 x 5 mm 
biopsy of the inferior bulbar conjunctiva was collected (6 o’clock 
position), fixed in formol and processed for histological analysis. 
The preparation of the slides has been previously 
described12. Briefly, slides were incubated at room temperature 
in a moist chamber using the primary monoclonal anti-HLA-DR 
antibody at a 1:50 concentration (Dako™, Glostrup, Denmark). 
Histological sections of human lymphoma were used as positive 
controls to examine the immunologic reaction. Negative controls 
consisted of the same histological sections but did not include the 
step of incubation with the primary antibody; this antibody was 
replaced with PBS.
Quantitative immunohistochemical analysis of HLA-DR 
expression was performed by image analysis using an Olympus 
BX41 trinocular microscope coupled with a CCD Samsung™ 
color camera (SDC-313/243) and PCTV software from the 
Pinnacle Media Center™. The images were analyzed using the 
Image J software (version 1.41, National Institutes of Health, 
USA)19. Cells were considered to be positive for the marker if a 
brown immunoprecipitate was present in the cytoplasm and/or on 
the cytoplasmic membrane. 
The cell counter method was used to count labeled cells 
directly from the monitor of the computer; marks of different 
colors were placed on the positive and negative cells with a click 
of the mouse. After the count, all data were exported to Excel 
2007® spreadsheets (Microsoft Corporation, USA), which provide 
the sum of the results of the count on one slide. At least 600 cells 
per biopsy were counted and the percentage of cells showing 
immunohistochemical expression of HLA-DR was calculated.
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The statistical analysis was performed using the Fisher´s 
Exact test and ANOVA (for differences between percentages of 
stained cells). Significant differences were considered when 
p<0.05.
Results
Biopsy samples were obtained from 31 eyes, from 
31 patients (22 male), with ages ranging from 50 to 76 years 
(median=66 years). Twenty five eyes were under prostaglandin 
analogue treatment (Group 1) and six were under the use of other 
pharmacological agents (Group 2) during the 30 days prior to 
the surgical procedure. The number of antiglaucoma eye drop 
preparations in use ranged from 1 to 4 (median 3) per eye, and 
the most frequently used medication was 0.5% timolol maleate 
(27 eyes). 
Fourteen eyes of Group 1 (56%) and three of Group 2 
(50%) presented conjunctival expression of the inflammatory 
marker HLA-DR (Figure 1). The percentage of stained cells ranged 
from 15.49 to 48.09% (median: 27.61) in Group 1 and from 18.35 
to 28% (median=20.71) in Group 2, and these differences were not 
statistically significant (p=0.33; IC 95%: 0.213 to 7.585). 
FIGURE 1 - Conjunctival biopsy showing positive labeling for the anti-
HLA-DR antibody (arrow). Magnification 400x.                                                 
Discussion
In the present study, the use of prostaglandin analogues 
was not a risk factor for conjunctival HLA-DR expression. In 
healthy subjects, conjunctival expression of Human Leucocitary 
Antigens (HLA) is low. But in patients under antiglaucomatous 
topical medication, HLA-DR and other inflammatory markers are 
detected even in the absence of clinical signs of inflammation, 
such as conjunctival hyperemia6-10,12-15.  
Although most of the similar studies found in the literature 
were performed with patients in use of prostaglandin analogues, 
it is currently accepted that BAK, a preservative widely used in 
ophthalmic preparations, play an important role in conjunctival 
inflammation20. 
Recently, it was described that patients presenting ocular 
side-effects due to topic prostaglandin analogues had a better 
tolerability when switching to a preservative-free prostaglandin 
solution (tafluprost)17. But although the percentage of patients 
presenting HLA-DR expression decreased, 87% of them were 
still expressing abnormal levels of HLA-DR after 12 weeks under 
preservative-free medication, which suggests that BAK is not the 
only factor involved in subclinical conjunctival inflammation. 
 In a previous publication, our group 
demonstrated a higher expression of conjunctival HLA-DR in eyes 
from patients in use of topic prostaglandin analogues for thirty or 
more days (94% of all eyes), although patients remained without 
any clinical sign of conjunctival inflammation12. In the current 
study, although most of the subjects under chronic medication 
presented conjunctival HLA-DR expression, the prevalence was 
lower (54.8% including all eyes, 56% considering only the group 
under prostaglandin analogues medication). This frequency could 
be explained by the differences in methodology (impression 
cytology versus biopsy).  Another potential explanation could be 
that subclinical inflammation is more frequent in early stages of 
the treatment. Rodrigues et al.12 observed HLA-DR expression 
in conjunctival cells 94% of the patients followed-up, after one 
month of treatment with prostaglandin analogues.
We decided to select patients with indication of 
trabeculectomy, so a conjunctival biopsy could be ethically 
justified at the moment of the surgery. That way, more cells can be 
analyzed than when an imprint is obtained. 
 One of the limitations of this study is the reduced 
number of patients, especially in Group 2.   For ethical reasons, 
the patients remained with the maximum tolerated treatment 
until the day of the surgery, when the specimens were collected. 
As prostaglandin analogues currently are the first choice drugs in 
antiglaucoma therapy3, most of the patients were under this type 
of medication. Thus, the present study was performed before 
the preservative-free prostaglandin tafluprost was commercially 
available, so the effect of this drug on conjunctival HLA-DR 
expression could not be evaluated.
The frequency of subclinical inflammation in both 
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groups suggests that this condition may be attributed to both, 
prostaglandin analogues and the vehicle of ophthalmic solutions 
used in glaucoma treatment (BAK). Further studies analyzing the 
expression of inflammatory markers in asymptomatic patients 
under preservative-free antiglaucoma medication should be 
performed in order to investigate if these medications, although 
causing less ocular symptoms, are able or not to produce 
subconjunctival inflammation and also to increase the risk of 
trabeculectomy failure.
Conclusion
HLA-DR conjunctival expression in eyes treated with 
prostaglandin analogs was not significantly different of the 
expression in eyes treated with other topical agents, used for 
glaucoma treatment.
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